{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:21:02Z","timestamp":1788326462291,"version":"build-2803163510"},"reference-count":27,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Sanofi"},{"name":"AstraZeneca"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>We read with interest the study by Kura et al [...]<\/jats:p>","DOI":"10.3390\/vaccines14090758","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:31:13Z","timestamp":1788251473000},"page":"758","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comment on Kura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. Vaccines 2026, 14, 411"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7298-6356","authenticated-orcid":false,"given":"Erin N.","family":"Hodges","sequence":"first","affiliation":[{"name":"Global Medical Affairs, Sanofi Vaccines US, Inc., Morristown, NJ 07960, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5101-3257","authenticated-orcid":false,"given":"Mehdi","family":"Ghemmouri","sequence":"additional","affiliation":[{"name":"Global Health Economics and Value Assessment, Sanofi Vaccines, 69007 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen P.","family":"Neary","sequence":"additional","affiliation":[{"name":"North America Health Economics and Value Access, Sanofi Vaccines US, Inc., Morristown, NJ 07960, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Gabriel","sequence":"additional","affiliation":[{"name":"North America Health Economics and Value Access, Sanofi Vaccines US, Inc., Morristown, NJ 07960, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Ottaviano","sequence":"additional","affiliation":[{"name":"North America Medical Affairs, Sanofi Vaccines US, Inc., Morristown, NJ 07960, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Mari","sequence":"additional","affiliation":[{"name":"Biostatistics, Sanofi Vaccines, 69007 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Ottobrino","sequence":"additional","affiliation":[{"name":"Global Health Economics and Value Assessment, Sanofi Vaccines, 69007 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman","family":"Chit","sequence":"additional","affiliation":[{"name":"North America Medical Affairs, Sanofi Vaccines US, Inc., Morristown, NJ 07960, USA"},{"name":"Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON M5S 3M2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Domachowske","sequence":"additional","affiliation":[{"name":"North America Medical Affairs, Sanofi Vaccines US, Inc., Morristown, NJ 07960, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Yarnoff","sequence":"additional","affiliation":[{"name":"Health Economics and Market Access, Evidera Inc., Wilmington, NC 28401, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6521-6967","authenticated-orcid":false,"given":"Robert","family":"Musci","sequence":"additional","affiliation":[{"name":"Health Economics and Market Access, Evidera Inc., Wilmington, NC 28401, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2325-5327","authenticated-orcid":false,"given":"Leonard R.","family":"Krilov","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Disease Researcher, Woodbury, NY 11797, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Kura, K., Lang, J.C., Wang, D., Choi, Y., Goveia, M.G., Sinha, A., Chen, Y.-H., and Elbasha, E.H. (2026). Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. Vaccines, 14.","DOI":"10.3390\/vaccines14050411"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa2502984","article-title":"Clesrovimab for Prevention of RSV Disease in Healthy Infants","volume":"393","author":"Zar","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1913556","article-title":"Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants","volume":"383","author":"Griffin","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJMc2214773","article-title":"Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants","volume":"388","author":"Muller","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2352-4642(22)00321-2","article-title":"Efficacy of Nirsevimab against Respiratory Syncytial Virus Lower Respiratory Tract Infections in Preterm and Term Infants, and Pharmacokinetic Extrapolation to Infants with Congenital Heart Disease and Chronic Lung Disease: A Pooled Analysis of Randomised Controlled Trials","volume":"7","author":"Simoes","year":"2023","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s40121-026-01311-w","article-title":"Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study","volume":"15","author":"Yarnoff","year":"2026","journal-title":"Infect. Dis. Ther."},{"key":"ref_8","unstructured":"Zhang, Y., Choi, Y., Railkar, R.A., Arriola, C.S., Petigara, T., Sim\u00f5es, E.A.F., Guerra, A., and Sinha, A. (2025, January 12\u201315). A Comparison of Two RSV-Associated Medically Attended Lower Respiratory Infection (RSV-MALRI) Definitions in a Phase 2b\/3 Trial (CLEVER) Evaluating the Safety and Efficacy of Clesrovimab. Proceedings of the 13th International RSV Symposium, Iguazu Falls, Brazil."},{"key":"ref_9","unstructured":"(2026, May 11). Multiple Endpoints in Clinical Trials, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/multiple-endpoints-clinical-trials."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","article-title":"Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6","volume":"15","author":"Briggs","year":"2012","journal-title":"Value Health"},{"key":"ref_11","unstructured":"(2026, June 03). NICE Technology Appraisal and Highly Specialised Technologies Guidance: The Manual. Available online: https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-technology-appraisal-and-highly-specialised-technologies-guidance-the-manual-pdf-72286779244741."},{"key":"ref_12","unstructured":"(2026, June 03). Choix M\u00e9thodologiques pour L\u2019\u00e9valuation Economique \u00e0 la HAS. Available online: https:\/\/www.has-sante.fr\/jcms\/p_3197550\/fr\/guide-2020-choix-methodologiques-pour-l-evaluation-economique-a-la-has."},{"key":"ref_13","unstructured":"Merck Sharp & Dohme LLC. (2026, May 11). ENFLONSIA (Clesrovimab-Cfor): Prescribing Information. Available online: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/e\/enflonsia\/enflonsia_pi.pdf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S2352-4642(25)00102-6","article-title":"180-Day Efficacy of Nirsevimab against Hospitalisation for Respiratory Syncytial Virus Lower Respiratory Tract Infections in Infants (HARMONIE): A Randomised, Controlled, Phase 3b Trial","volume":"9","author":"Munro","year":"2025","journal-title":"Lancet Child Adolesc. Health"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/jcph.2401","article-title":"Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants","volume":"64","author":"Clegg","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e2024067174","DOI":"10.1542\/peds.2024-067174","article-title":"RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing","volume":"154","author":"Wilkins","year":"2024","journal-title":"Pediatrics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1001\/jamapediatrics.2025.5778","article-title":"Effectiveness and Impact of Maternal RSV Immunization and Nirsevimab on Medically Attended RSV in US Children","volume":"180","author":"Moline","year":"2026","journal-title":"JAMA Pediatr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1473-3099(25)00233-6","article-title":"Effectiveness and Impact of Nirsevimab in Chile during the First Season of a National Immunisation Strategy against RSV (NIRSE-CL): A Retrospective Observational Study","volume":"25","author":"Torres","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Buey, J.F.B.D., Mart\u00ednez, J.\u00cd., Rodr\u00edguez, M.\u00c1.G., Garc\u00eda, M.A., S\u00e1nchez-G\u00f3mez, A., Carbajo, M.D.L., Bueno, S.J., Vasallo, M.D.E., Zambrano, M.A.L., and Rey, C.C. (2024). The Effectiveness of Nirsevimab in Reducing the Burden of Disease Due to Respiratory Syncytial Virus (RSV) Infection over Time in the Madrid Region (Spain): A Prospective Population-Based Cohort Study. Front. Public Health, 12.","DOI":"10.3389\/fpubh.2024.1441786"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00431-025-06151-3","article-title":"Respiratory Syncytial Virus\u2013Related Lower Respiratory Tract Infection Hospitalizations in Infants Receiving Nirsevimab in Galicia (Spain): The NIRSE-GAL Study","volume":"184","author":"Manzanares","year":"2025","journal-title":"Eur. J. Pediatr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.1093\/infdis\/jiae581","article-title":"A Phase 1b\/2a Trial of a Half-Life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-Term Infants","volume":"231","author":"Madhi","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_22","unstructured":"Sanofi Pasteur Limited (2026, June 10). BEYFORTUS (Nirsevimab Injection). Available online: https:\/\/www.sanofi.com\/assets\/countries\/canada\/docs\/products\/vaccines\/beyfortus-en.pdf."},{"key":"ref_23","unstructured":"Sanofi-Aventis U.S. LLC. (2026, May 11). BEYFORTUS (Nirsevimab-Alip): Prescribing Information. Available online: https:\/\/products.sanofi.us\/beyfortus\/beyfortus.pdf."},{"key":"ref_24","unstructured":"Center for Drug Evaluation and Research (2026, April 08). Integrated Review: Enflonsia (Clesrovimab-cfor), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/761432Orig1s000IntegratedR.pdf."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1080\/14760584.2025.2591816","article-title":"Comparison of the Public Health Impact of RSV Disease Prevention Options for Infants: A Static Decision Model of the US Birth Cohort","volume":"24","author":"Kieffer","year":"2025","journal-title":"Expert Rev. Vaccines"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2024066461","DOI":"10.1542\/peds.2024-066461","article-title":"Cost-Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children","volume":"154","author":"Hutton","year":"2024","journal-title":"Pediatrics"},{"key":"ref_27","unstructured":"Moulia, D. (2026, May 11). Evidence to Recommendations Framework: Clesrovimab, Available online: https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-06-25-26\/05-MacNeil-Mat-Peds-RSV-508.pdf."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/758\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:38:59Z","timestamp":1788323939000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["vaccines14090758"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14090758","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}